Torrent Pharma posts PAT at Rs 287 crore in Q4
The board also approved a final dividend of Rs 8 per share of Rs 5 each.
Ahmedabad: Torrent Pharma on Tuesday reported a consolidated profit after tax of Rs 287 crore for the fourth quarter ended March 2023, riding on robust sales across geographies.
The drug maker had reported a net loss of Rs 118 crore in the January-March quarter of the 2021-22 fiscal.
The company's revenue rose to Rs 2,491 crore for the fourth quarter compared to Rs 2,131 crore in the year-ago period, Torrent Pharma said in a statement.
For the year ended March 2023, the drug maker posted a profit after tax of Rs 1,245 crore against Rs 777 crore in FY22.
The revenue rose to Rs 9,620 crore last fiscal from Rs 8,508 crore in 2021-22.
The company said its board recommended to the members to obtain enabling approval for the issuance of shares, including convertible bonds/ debentures through qualified institutional placement (QIP) and/or depository receipts or any other modes for an amount not exceeding Rs 5,000 crore.
The board also approved a final dividend of Rs 8 per share of Rs 5 each.
Read also: Torrent Pharma unveils generic version of Keveyis tablets in US
Torrent Pharma is an Indian multinational pharmaceutical company headquartered in Ahmedabad, India. The company specializes in the therapeutic segments of cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), and women healthcare (WHC). The Company also has a significant presence in diabetology, pain management, gynaecology, oncology, and anti-infective segments.Torrent Pharma has a widespread global presence in over 40 countries.
Read also: Torrent Pharma Shelcal 500 enters market as OTC calcium supplement brand
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd